Invasive Fungal Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Issue 7 (October 2016)

• Record Type: Journal Article
• Authors: Aftandilian, Catherine; Weinberg, Kenneth; Willert, Jennifer; Kharbanda, Sandhya; Porteus, Matthew; Maldonado, Yvonne; Agarwal, Rajni
• Is Part Of: Journal of pediatric hematology/oncology. Volume 38:Issue 7(2016)
• Publication Date: 2016-10
• Subjects: fungal disease -- stem cell transplant -- voriconazole; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000000629
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Invasive fungal disease (IFD) remains a major cause of morbidity and mortality in pediatric patients after allogeneic hematopoietic stem cell transplant (HSCT). We analyzed the outcome of 152 consecutive pediatric patients who underwent allogeneic HSCT from 2005 to 2012: 126 of these without a history of IFD and 26 with IFD before HSCT. Antifungal prophylaxis agent was determined by the primary transplant attending. The rate of IFD after HSCT among patients with or without prior IFD was similar (7.7% with and 7.1% without a history of fungal disease before transplant). Mortality in these 2 populations did not differ (35% vs. 28%, P =0.48, χ 2 ). Patients deemed at higher risk for IFD were generally placed on voriconazole prophylaxis; however, this did not affect rates of posttransplant IFD. All-cause mortality in patients with posttransplant IFD was significantly higher than those without posttransplant IFD (67% vs. 21%, P <0.0001, χ 2 ). Identifying risk factors for posttransplant IFD remains a high priority to improve outcome of HSCT.